Nuvig Therapeutics Closes $47M Series B Financing

Nuvig Therapeutics

Nuvig Therapeutics, a Redwood City, CA-based company specializes in developing therapies that stimulate immune homeostasis. These therapies can be used to treat autoimmune disorders without compromising normal immune function.

Novo Holdings A/S led the round, as did Platanus. Participants included Mission BioCapital, Digitalis Ventures and Bristol Myers Squibb.

The company plans to use the funds for its development efforts.

Led by Pamela Conley, Ph.D., Chief Executive Officer, Nuvig Therapeutics offers protein therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following inflammation, and improve the treatment options for patients. Nuvig is developing a pipeline for immune therapies for chronic inflammatory or autoimmune diseases.

Get latest news from African Startup ecosystem

Latest stories

You might also like...